ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER

摘要

The therapeutic combinations of leukotriene (LTB4) antagonists, which have an IC50 less than 10 nanomolar for inhibition of binding of <3>H-LTB4 to human neutrophils and anti-cancer agents are disclosed. A method of treating cancer using leukotriene (LTB4) antagonists which have an IC50 less than 10 nanomolar for inhibition of binding of <3>H-LTB4 to human neutrophils, in conjunction with anti-cancer agents is also disclosed.